| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA682: Erenumab for preventing migraine |
|
Medicine details |
|
| Medicine name | erenumab (Aimovig®) |
| Formulation | 70 mg solution for injection |
| Reference number | 2843 |
| Indication | Prophylaxis of migraine in adults who have at least 4 migraine days per month |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/06/2018 |
| NICE guidance | |